The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine
SuspendedNot applicableNCT04064879
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The present study is being undertaken as a phase I study to determine the safety and feasibility of using adipose derived mesenchymal stem cell preparations (MSC) for treatment of CM. Intravenous and locally targeted stem cell treatment have already been reported in the context of treating various chronic pain conditions with early evidence of efficacy and a good safety profile. The treatment of CM is based on the model for treatment with botulinum where superficial facial and cranial injections are utilized. In addition, stem cells can be given intravenously as well.
Study details
- Official title
- The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine
- Conditions
- Interventions
- Other: AD-SVF
- Sponsor
- Neurological Associates of West Los Angeles
- Collaborators
- Cell Surgical Network Inc.
- Start date
- 2018-08-16
- Primary completion
- 2023-08-15
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients must exhibit symptoms that satisfy criteria of Chronic Migraine (e.g., experiencing headaches at least 15 days per month to a degree that is associated with significant disability and reduced health-related quality of life). Exclusion Criteria: * Advanced stages of any terminal illness or active cancer that requires chemotherapy. * Pregnancy, women who may become pregnant or are breastfeeding. * Bleeding disorder, untreated.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04064879